Replies to post #277362 on Anavex Life Sciences Corp (AVXL)

[tootalljones]

great post falconer.

[nidan7500]

falconer66a Brilliant assessment.

Miyamoto Musashi would be very proud of such a strategy. He (Dr.M.) has his opponents surrounded, and they do not yet know what is about to happen. Brilliant strategy.

Once and for all, this clever maneuver will validate and confirm the blarcamesine mechanism(s) of action, facilitating favorable activation of the sigma-1 receptor protein. The Alzheimer's people are going to see the quite favorable Parkinson's results, and then have to explain to various Alzheimer's stakeholders why they haven't taken this approach to Alzheimer's. "Wow, look at what that drug did for people with Parkinson's. And Anavex is testing it on people with Alzheimer's. No doubt, blarcamesine is now in the Alzheimer's game."

[vg_future]

falconer66a, good logic. Stretching the logic a bit more....I expect some PD or PDD related info from Anavex before or immediately after the conference to put things in proper perspective (kind of official vouching of Anavex's PDD results). Any thoughts along those line? TIA

-vg_future

[baltimorebullet]

It certainly answers the question "are the results good?

[Penny Double]

"When you look back and see why I did the things the way I did "

Very well planned out doc!!!! Sit back, the train leaving the station.

[abew4me]

Has this ever been done before?

Seriously...has other biotech companies scheduled a conference at a CTAD Alzheimer conference to release the results of their phase 2 trial from another disease unrelated to Alzheimers?

[Turner2017]

Post of the day. IMO Missling couldve included the data in the PR or present it at any PD conference but he chose CTAD!

I dont think anyone put down CTAD as a possible choice before this announcement. Very exciting times ahead!